$1.50
+0.00 (+0.00%)
Open$1.49
Previous Close$1.50
Day High$1.55
Day Low$1.46
52W High$43.45
52W Low$27.61
Volume—
Avg Volume363.8K
Market Cap4.07M
P/E Ratio57.54
EPS$0.56
SectorBiotechnology
Analyst Ratings
Strong Sell
8 analysts
Price Target
+2,295.3% upside
Current
$1.50
$1.50
Target
$35.93
$35.93
$28.98
$35.93 avg
$50.96
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.55M | 1.36M | 1.68M |
| Net Income | 56.6K | 59.8K | 87.7K |
| Profit Margin | 3.7% | 4.4% | 5.2% |
| EBITDA | 150.2K | 130.3K | 163.2K |
| Free Cash Flow | 63.5K | 61.7K | 63.4K |
| Rev Growth | -6.9% | +10.8% | +11.9% |
| Debt/Equity | 0.70 | 0.59 | 0.72 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |